- Home
- TGTX vs FRO Comparison
TGTX vs FRO Comparison
Compare TGTX & FRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- FRO
- Stock Information
- Founded
- TGTX 1993
- FRO 1985
- Country
- TGTX United States
- FRO Cyprus
- Employees
- TGTX N/A
- FRO N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- FRO Marine Transportation
- Sector
- TGTX Health Care
- FRO Consumer Discretionary
- Exchange
- TGTX Nasdaq
- FRO Nasdaq
- Market Cap
- TGTX 5.1B
- FRO 5.2B
- IPO Year
- TGTX 1995
- FRO N/A
- Fundamental
- Price
- TGTX $36.73
- FRO $21.85
- Analyst Decision
- TGTX Strong Buy
- FRO Strong Buy
- Analyst Count
- TGTX 6
- FRO 3
- Target Price
- TGTX $47.50
- FRO $25.00
- AVG Volume (30 Days)
- TGTX 1.9M
- FRO 2.3M
- Earning Date
- TGTX 11-03-2025
- FRO 11-26-2025
- Dividend Yield
- TGTX N/A
- FRO 8.11%
- EPS Growth
- TGTX N/A
- FRO N/A
- EPS
- TGTX 0.36
- FRO 1.07
- Revenue
- TGTX $454,069,000.00
- FRO $1,823,905,000.00
- Revenue This Year
- TGTX $82.22
- FRO N/A
- Revenue Next Year
- TGTX $47.76
- FRO $22.16
- P/E Ratio
- TGTX $101.18
- FRO $21.49
- Revenue Growth
- TGTX 30.96
- FRO N/A
- 52 Week Low
- TGTX $21.16
- FRO $12.40
- 52 Week High
- TGTX $46.48
- FRO $25.68
- Technical
- Relative Strength Index (RSI)
- TGTX 72.14
- FRO 44.45
- Support Level
- TGTX $34.52
- FRO $22.28
- Resistance Level
- TGTX $37.45
- FRO $23.22
- Average True Range (ATR)
- TGTX 1.10
- FRO 0.61
- MACD
- TGTX 0.59
- FRO -0.25
- Stochastic Oscillator
- TGTX 90.30
- FRO 15.79
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About FRO Frontline Plc
Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.